FORMULÆ

THE ART & SCIENCE OF COMPOUNDING

CJC-1295/Ipamorelin

CJC-1295 2mg/mL + Ipamorelin 2mg/mL

This leaflet provides important information about using CJC-1295 + Ipamorelin.

You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using CJC-1295 + Ipamorelin.

WHY AM I USING [MEDICINE NAME]?

CJC-1295 + Ipamorelin contains the active ingredient CJC-1295 and Ipamorelin. CJC-1295 + Ipamorelin is a combination of synthetic peptides that enhance natural growth hormone release.

CJC-1295 + Ipamorelin is used to support age-related GH decline, improve muscle recovery, enhance metabolism and sleep, and assist in anti-ageing protocols.

It has been compounded specifically for you as there is no equivalent or suitable TGA-approved medicine commercially available in Australia

WHAT SHOULD I KNOW BEFORE I USE

WARNINGS

Do not use CJC-1295 + Ipamorelin if:

- you are allergic to CJC-1295 or Ipamorelin or benzyl alcohol, or any of the ingredients listed at the end of this leaflet.
- Always check the ingredients to make sure you can use this medicine.
- You have active or suspected cancer, untreated thyroid, adrenal, or pituitary disorders.
- You are pregnant or breastfeeding

CHECK WITH YOUR DOCTOR IF YOU:

- have any other medical conditions thyroid disorders, adrenal disorders, pituitary gland conditions
- take any medicines for any other condition
- Blood tests may be required periodically to monitor IGF-1 levels, thyroid, and liver function..

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section Are there any side effects?

PREGNANCY AND BREASTFEEDING

Check with your doctor if you are pregnant or intend to become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

WHAT IF I AM TAKING OTHER MEDICINES?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

HOW DO I USE CJC-1295 + Ipamorelin?

HOW MUCH TO TAKE /USE

• Follow the instructions provided when CJC-1295 + Ipamorelin was prescribed, including the number of days it should be taken.

WHEN TO TAKE / USE [MEDICINE NAME]

 CJC-1295 + Ipamorelin should be used once daily, five days per week (e.g., Monday to Friday).



FORMULÆ

HOW TO INJECT

 Inject the prescribed amount (0.1 mL to 0.2 mL) subcutaneously into the abdomen or thigh. Rotate injection sites. Use aseptic technique and sterile equipment.

IF YOU FORGET TO USE

CJC-1295 + Ipamorelin should be used regularly at the same time each day [week or month]. If you miss your dose at the usual time, take your next dose as scheduled. Do not double dose..

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Do not take a double dose to make up for the dose you missed.

IF YOU USE TOO MUCH

If you think that you have used too much CJC-1295 + Ipamorelin, you may need urgent medical attention.

You should immediately:

- phone the Poisons Information Centre (by calling 13 11 26), or
- contact your doctor, or
- go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

WHAT SHOULD I KNOW WHILE USING CJC-1295 + Ipamorelin?

THINGS YOU SHOULD DO

Follow your doctor's dosage instructions and attend regular check-ups for monitoring IGF-1 and hormone levels.

Call your doctor straight away if you:

• Report any unusual symptoms, such as joint pain or swelling, to your doctor.

• If symptoms persist or worsen, contact your healthcare provider promptly.

Remind any doctor, dentist or pharmacist you visit that you are using CJC-1295 + Ipamorelin.

THINGS YOU SHOULD NOT DO

 Do not exceed the prescribed dose or share your medication.

DRIVING OR USING MACHINES

Be careful before you drive or use any machines or tools until you know how CJC-1295 + Ipamorelin affects you.

This medicine may cause drowsiness in some people.

DRINKING ALCOHOL

Tell your doctor if you drink alcohol. Alcohol may reduce the effectiveness of the treatment.

Precautions and Monitoring

- Always follow your doctor's dosage instructions
- Report any new or unusual symptoms
- Do not inject more than the recommended dose
- Do not double-dose to make up for missed doses
- Blood tests may be required periodically to monitor IGF-1 levels, Liver function, and thyroid balance

LOOKING AFTER YOUR MEDICINE

- Store in the refrigerator (2°C to 8°C). Do not freeze.
- Protect from light. Discard 30 days after opening.
- For single-patient use only- not to be shared.

Follow the instructions on how to take care of your medicine properly.



FORMULÆ

THE ART & SCIENCE OF COMPO

Do not store it:

- in the bathroom or near a sink, or
- in the car or on window sills.

Keep it where young children cannot reach it.

WHEN TO DISCARD YOUR MEDICINE (AS RELEVANT)

Discard 30 days after first use.

GETTING RID OF ANY UNWANTED MEDICINE

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

ARE THERE ANY SIDE EFFECTS?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

LESS SERIOUS SIDE EFFECTS

LESS SERIOUS SIDE EFFECTS	WHAT TO DO
 Mild pain, itching, or redness at the injection site Localized swelling Light-headedness or dizziness post injection 	Speak to your doctor if you have any of these less serious side effects and they worry you.

SERIOUS SIDE EFFECTS

SEF	RIOUS SIDE EFFECTS	WHAT TO DO
С	welling of the lips, face, or tongue rersistent fever or chills	Call your doctor straight away or go straight to the Emergency

- Sever redness or inflammation at the injection site
- Joint or bone pain
- Dizziness associated with low blood pressure
- Generalized rash or breathing difficulty

Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

REPORTING SIDE EFFECTS

After you have received medical advice for any side affects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

PRODUCT DETAILS

This medicine is only available with a doctor's prescription.

WHAT CONTAINS

Active ingredient	CJC-1295 Ipamorelin
Other ingredients	Benzyl alcohol Sterile water

Do not take this medicine if you are allergic to any of these ingredients.



FORMULÆ THE ART & SCIENCE OF COMPOUNDING

PHARMACY CONTACT

The Compounding Lab 45 Crosby Rd, Albion, QLD, 4010 +617 3862 6000

References

Teichman SL et al. "Prolonged Stimulation of Growth Hormone and IGF-1 Secretion by CJC-1295 in Healthy Adults." *J Clin Endocrinol Metab.* 2006;91(3):799–805. <u>https://doi.org/10.1210/jc.2005-1536</u>

PubChem Database – Molecular Information on CJC-1295 and Ipamorelin <u>https://pubchem.ncbi.nlm.nih.gov</u>

ClinicalTrials.gov – Studies on CJC-1295 and Ipamorelin

https://www.clinicaltrials.gov

Tailor Made Compounding Peptide Catalog, 2024 Edition – Pages 17–18. <u>https://www.tailormadecompounding.co</u> <u>m</u>

Australian Medicines Handbook – Endocrine and Hormonal Therapy Section <u>https://www.amh.net.au</u>

MedlinePlus (US National Library of Medicine) – Peptides in Clinical Use <u>https://medlineplus.gov</u>

TGA Guidelines for Compounded Medicines

https://www.tga.gov.au/resources/resourc e/guidance/guidance-compoundedmedicines

This leaflet was prepared in April 2025.

